Navigation Links
InspireMD Appoints Rick Olson as Vice President of Global Sales Operations
Date:12/2/2013

BOSTON, Dec. 2, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a leader in embolic protection systems, today announced the appointment of Rick Olson as Vice President of Global Sales Operations based in the United Kingdom.

Mr. Olson, 52, will be responsible for fully implementing the global sales strategy the Company has developed over the past several months. Also, his extensive experience in coronary, vascular and peripheral product sales will enable the Company to begin to advance commercial efforts across all three therapeutic areas.

Mr. Olson is a 25-year global sales, marketing and management executive with expertise in developing and executing strategies to achieve scalable growth for an array of novel medical device technology companies, including Boston Scientific and Covidien. Prior to joining InspireMD, Mr. Olson served as the Director of International Strategy and HPMS (High Performance Management System) at Covidien. Before it was acquired by Covidien, Mr. Olson was Director of International Neurovascular Marketing & Sales Force Development at ev3, Inc., where he initiated market development and sales execution strategies for all OUS markets. During his tenure with ev3, revenues increased from less than $5 million to over $400 million in sales leading up to the acquisition of ev3 by Covidien in 2008. Prior to that, Mr. Olson spent nine years at Boston Scientific where he served in various sales and marketing leadership positions both in Europe and the United States. Mr. Olson holds a Bachelor's Degree in Psychology from Oregon State University.

"We are delighted to have Rick join the team at this important time in the Company's commercialization efforts," commented Alan Milinazzo<
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... ... June 29, 2015 , ... OR Manager announced Monday the ... and feel, as well as a redesigned logo and weekly eLetter. The website contains ... now more user-friendly and easier to navigate. , In addition to a refreshed ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... (Cognizin®) from Kyowa Hakko Bio to French consumers. , The specialized eye health ... oxidative stress caused by free radicals. In addition to Citicoline (Cognizin®), Biomacula provides ...
(Date:6/29/2015)... ... June 29, 2015 , ... FACE is proud to be one of ... reduction of the double chin and redefining of the jawline. Excess fat under ... older and heavier causing the person distress and poor self-image. , Kybella was produced ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... plumbing company serving the Twin Cities area, provides money-saving tactics during a season ... for Twin Cities’ residents, addressing water conservation and other economical practices. , According ...
(Date:6/29/2015)... ... June 29, 2015 , ... Wheel:Life, ... Travel Guide for Wheelchair Users as a new e-book on Amazon.com. Wheel:Life publications ... , These accessible travel suggestions were crowdsourced by the Get Out & Enjoy ...
Breaking Medicine News(10 mins):Health News:OR Manager Launches New Website 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:FACE Detroit Skin and Wellness Clinic Introduces Newly FDA Approved Kybella for the elimination of the Double Chin. 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 2Health News:Save Energy: MSP Plumbing, Heating & Air Endorses Efficiency 3Health News:Wheel:Life Publishes Accessible US Travel Guidebook for Wheelchair Users 2Health News:Wheel:Life Publishes Accessible US Travel Guidebook for Wheelchair Users 3
... Elsevier, a world-leading healthcare and scientific publisher, announced ... Tarrytown, New York based InfoDesk to co-develop a ... life science companies. The combination of Elsevier,s ... the way for the development of a powerful ...
... ST. PAUL (June 8, 2010) A University of Minnesota ... can count on an increased life expectancy. The research is ... of Surgery . The findings stem from the Program ... which kicked off at the University of Minnesota in 1975. ...
... June 2010 The Institute for Research in Immunology ... B2Discovery, a new research funding model that brings together ... help accelerate the discovery of new anti-cancer therapeutics. Inspired ... Canadian athletes at the Vancouver Winter Olympics, B2Discovery,s mission ...
... Jose, CA, June 7, 2010 Chronix Biomedical today ... blood tests have the potential to accurately detect early ... technology identifies disease-specific genetic fingerprints based on circulating DNA ... and dying (apoptotic) cells. In this new study ...
... build up a big sweat to reap the healing ... a low-intense exercise program can reduce depression symptoms and ... "The power of physical activity to raise the ... suspected," Heart and Stroke Foundation researcher Dr. Jocelyn Harris ...
... School of Public Health (HSPH) have found that children ... laws promoting smoke-free public places have significantly lower levels ... those living in counties with no smoke-free laws. ... with smoke-free laws had 39% lower prevalence of cotinine ...
Cached Medicine News:Health News:Elsevier and InfoDesk collaborate to co-develop federated drug pipeline intelligence solution 2Health News:B2Discovery: Entrepreneurs and researchers join forces to conquer cancer 2Health News:ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity 2Health News:ASCO data show serum DNA blood tests detect cancers with high sensitivity and specificity 3Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 2Health News:Non-intense physical activity to reduce depression and boost recovery of stroke patients 3Health News:Smoke-free air laws effective at protecting children from secondhand smoke 2
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: